Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic <i>EGFR</i>-Mutant Lung Cancers
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Mark G. Kris(American Society of Clinical Oncology), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Robert J. Young(Memorial Sloan Kettering Cancer Center), Dana W.Y. Tsui(Memorial Sloan Kettering Cancer Center), Julie L. Yang(Memorial Sloan Kettering Cancer Center), Sara A. Hayes(Memorial Sloan Kettering Cancer Center), Yosef Y. Tobi(Cornell University), Glenn Heller(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Brian Houck‐Loomis(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Linda S. Ahn(Cornell University), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Alex Makhnin(Memorial Sloan Kettering Cancer Center), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Rachel Kim(Memorial Sloan Kettering Cancer Center), Christina J. Falcon(Memorial Sloan Kettering Cancer Center), Fanli Meng(Memorial Sloan Kettering Cancer Center), Hira Rizvi(Memorial Sloan Kettering Cancer Center)
Cited by 131
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k